Successful pregnancies in patients with BCR-ABL-positive leukemias treated with interferon-alpha therapy during the tyrosine kinase inhibitors era.
Marie BalsatMadeleine EtienneMohamed ElhamriSandrine HayetteGilles SallesXavier G ThomasPublished in: European journal of haematology (2018)
Because of the increased risk of teratogenicity and spontaneous abortion in female patient with pregnancy, when receiving TKI, IFN-alpha can be considered a safe drug to be administered throughout pregnancy and could represent the drug of choice in this situation during the era of TKI therapy.
Keyphrases
- chronic myeloid leukemia
- tyrosine kinase
- preterm birth
- pregnancy outcomes
- dendritic cells
- epidermal growth factor receptor
- advanced non small cell lung cancer
- acute lymphoblastic leukemia
- immune response
- case report
- adverse drug
- pregnant women
- gestational age
- mesenchymal stem cells
- smoking cessation
- electronic health record